



















httpPlasma metabolomic proﬁles predict near-term
death among individuals with lower extremity
peripheral arterial disease
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Background: Individuals with peripheral arterial disease (PAD) have a nearly two-fold increased risk of all-cause and
cardiovascular disease mortality compared to those without PAD. This pilot study determined whether metabolomic
proﬁling can accurately identify patients with PAD who are at increased risk of near-term mortality.
Methods: We completed a case-control study using 1H NMR metabolomic proﬁling of plasma from 20 decedents with
PAD, without critical limb ischemia, who had blood drawn within 8 months prior to death (index blood draw) and within
10 to 28 months prior to death (preindex blood draw). Twenty-one PAD participants who survived more than 30 months
after their index blood draw served as a control population.
Results: Results showed distinct metabolomic patterns between preindex decedent, index decedent, and survivor samples.
The major chemical signals contributing to the differential pattern (between survivors and decedents) arose from the fatty
acyl chain protons of lipoproteins and the choline head group protons of phospholipids. Using the top 40 chemical signals
for which the intensity was most distinct between survivor and preindex decedent samples, classiﬁcation models predicted
near-term all-cause death with overall accuracy of 78% (32/41), a sensitivity of 85% (17/20), and a speciﬁcity of 71% (15/
21). When comparing survivor with index decedent samples, the overall classiﬁcation accuracy was optimal at 83% (34/41)
with a sensitivity of 80% (16/20) and a speciﬁcity of 86% (18/21), using as few as the top 10 to 20 chemical signals.
Conclusions: Our results suggest that metabolomic proﬁling of plasma may be useful for identifying PAD patients at
increased risk for near-term death. Larger studies using more sensitive metabolomic techniques are needed to identify
speciﬁc metabolic pathways associated with increased risk of near-term all-cause mortality among PAD patients. (J Vasc
Surg 2013;58:989-96.)Lower extremity peripheral arterial disease (PAD)
affects eight million men and women in the United States
and is expected to increase in prevalence as the U.S. popu-
lation survives longer with chronic disease.1 Men and
women with PAD have a higher risk for all-cause and
cardiovascular disease (CVD) mortality than men and
women without PAD, even after adjusting for CVD risk
factors and comorbidities.2,3 Despite optimal atheroscle-
rotic disease risk factor control, many patients with
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://dx.doi.org/10.1016/j.jvs.2013.04.022cardiovascular risk factors are useful to predict long-term
coronary events and mortality, but are less useful for pre-
dicting near-term events.4-7
Many acute coronary events result from plaque rupture
and lumen thrombosis at arterial sites with minimally
occlusive atherosclerosis.8 Circulating inﬂammatory and
hemostatic biomarkers may contribute to plaque instability
and rupture.9-11 However, these associations are not clearly
established. Identifying biomarkers that are elevated imme-
diately prior to an acute coronary event could provide
important short-term prognostic information and may
elucidate mechanisms of acute coronary events.
Metabolites are the end products of complex interac-
tions between the host genome and environmental stimuli.
Thus, metabolic changes are the most proximal reporters of
an individual’s physiological status (such as an acute coro-
nary event). Identifying novel metabolic pathways that are
activated immediately prior to death may help establish
new mechanisms of mortality that may be targeted with
novel therapies to prevent adverse outcomes in patients
with PAD. Metabolomics,12 a relatively new “omics”
system, provides an unbiased means to probe the full spec-
trum of the metabolic pattern. Metabolomics holds great
potential to discover major chemical alterations in response
to physiological changes and guide the selection of thera-
peutic targets.13,14 Thus, metabolomics represents a poten-
tially powerful tool to capture molecular events that deﬁne
distinct populations of patients and to attain a high prog-
nostic accuracy for near-term events such as death.989
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nuclear magnetic resonance (1H NMR) metabolomic
proﬁles of plasma between PAD patients who died within
8 months of a blood draw and PAD patients who survived
for at least 30 months after a blood draw. We hypothesized
that metabolomic proﬁles of plasma can differentiate PAD
patients with vs without increased risk of near-term death.
METHODS
Study participants and blood sample selections.
The study protocol was approved by the institutional
review boards of Northwestern University’s Feinberg
School of Medicine and participating study sites. Partici-
pants gave written informed consent. PAD participants
were selected from existing cohorts of outpatients with
PAD at Northwestern University including the Walking
and Leg Circulation Study (WALCS), II, III cohorts, the
Study to Improve Leg Circulation (SILC), and the
Reducing Risk Factors in Peripheral Arterial Disease
(RRF) study. Detailed descriptions of the WALCS, SILC,
and RRF study designs and methods have been published
previously.15-18 Across these studies, PAD was deﬁned as
an ankle-brachial index <0.95, documented evidence of
lower extremity revascularization, or documented clinical
evidence of lower extremity atherosclerosis.
The current study consists of 20 PAD participants who
died within 8 months of their last study blood draws (dece-
dents) and 21 gender- and age-matched (within 3 years)
PAD controls (survivors). Decedents died between May 1,
2000 and December 31, 2008. We selected all decedents
from the WALCS, SILC, and RRF cohorts who met the
following criteria: (a) presence of two blood draws (eg,
index and preindex blood draws) prior to death; (b) the
ﬁnal blood draw (index blood draw) was within 1 year
before death; and (c) the presence of a matched control
survivor PAD participant. The index blood draw is deﬁned
as the blood draw that occurred closest to death (2-8
months preceding death). The preindex blood draw is
deﬁned as the blood draw at the study visit immediately
prior to the index blood draw. The preindex blood draws
occurred 7 to 25 months prior to the index blood draws.
Each control PAD participant (survivor) was also selected
from one of the same cohorts (WALCS I, II, or III, SILC,
or RRF) and met the following criteria for inclusion in the
study: a) presence of one blood sample that was matched
for date of blood draw to within 3 months of the date of
the decedent’s index blood draw date; survival to at least
30 months (mean 6 standard deviation [sd], 67 6 28
months) after the date of their blood draws. There were
a total of 61 blood samples for the metabolomics experi-
ment, two for each decedent and one for each survivor.
Ascertainment of mortality. Deaths were identiﬁed
using the Social Security Administration death database
and by contact with participants’ family members, proxies,
and primary care physicians. Cause of death was deter-
mined using death certiﬁcates and by a certiﬁed nosologist.
Cardiovascular deaths were those with International Classi-
ﬁcation of Disease-10 codes in the ranges I01.0 throughI99.9, including deaths due to coronary heart disease,
stroke, peripheral vascular disease, and other CVD.
Plasma sample preparation. Blood was collected into
Vacutainer (Becton Dickinson, Franklin Lakes, NJ) tubes
containing EDTA and sodium citrate and immediately
placed on ice. The plasma was separated immediately by
centrifugation at 3000 rpm for 20 minutes at 4C and
samples were frozen and stored at 70C.
Measurement of clinical variables. The clinical vari-
ables and blood biomarkers for the current study include
ankle-brachial index, total and high density lipoprotein
cholesterol levels, D-dimer, CRP, cigarette smoking,
body mass index, and medical history. CRP and D-dimer
data were only available for 16 survivors and 16 decedents
from the WALCS and WALCS II cohorts. The details for
calculation and acquisition of all these measures for each
study have been reported previously15-20 and are
described brieﬂy in the Appendix (online only).
Plasma 1H NMR spectroscopy protocol and quality
control. For each plasma sample, 550 mL of plasma and
saline (0.9%) mixture was used for the 1H NMR spectrum
measurement at 600.13 MHz on a Bruker DRX-600
spectrometer (Bruker Corporation, Billerica, Mass). The
water resonance was suppressed. The experimental
temperature was set at 298 k.
1H NMR spectra of plasma were acquired using both
Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence and
diffusion-edited sequence.21 Diffusion-edited sequence of
the 1H NMR spectrum characterized the lipid molecules
of lipoproteins, such as the eCH3 group of trigelycerides,
cholesterols, phospholipids, and glycophospholipids to
generate broad resonances in the spectrum. To characterize
the small molecules such as creatinine, lactate, and glucose,
we used the spectrometer with CPMG pulse sequence to
detect the low molecular weight molecules by suppressing
most of the broad resonances. The spectrum from both
small molecules and lipoproteins generates an overall
chemical structural proﬁle.
Metabolomics data preprocessing, normalization,
and statistical analysis. All spectra were phase-corrected
and referenced to the chemical shift of alpha-glucose
anomeric doublet at 5223 parts per million (ppm). Base-
line correction was also applied to each spectrum using
a penalized smoothing method.22 Each spectrum was
segmented into 1000 chemical shift regions with a binning
size 0.01 ppm in the range of chemical shift d 0-10 for all
data analysis. The peak region of water signal between
d 4.5 to 5.2 ppm was removed prior to statistical analysis.
Statistical analysis of plasma 1H NMR spectral data was
performed with R 2.10 (R Development Core Team;
http://www.R-project.org) using several data analysis
strategies, as described below. All binned NMR spectral
data were logged and normalized with a quantile normali-
zation procedure. Identiﬁcation of differential chemical
signals (ie, binned variables) was performed using two-
sample or paired t-tests as appropriate. Detailed statistical
methods for metabolomics data analysis regarding chemical
signal selection for sample classiﬁcation are described in the
Table. Baseline clinical characteristics of peripheral arterial disease (PAD) participants, according to whether they were
decedents vs survivors
Variables Decedent (n ¼ 20) Survivor (n ¼ 21) P valuea
Age, years 75.9 6 7.8 73.9 6 8.0 .42
Male, % 80 (16/20) 81 (17/21) .99
Ankle-brachial index 0.74 6 0.24 0.73 6 0.20 .94
Body mass index, kg/m2 26.5 6 5.3 25.3 6 3.5 .38
Total cholesterol, mg/dL 168.8 6 38.1 173.0 6 22.9 .70
High-density lipoproteins, mg/dL 41.1 6 11.0 43.2 6 17.6 .67
CRP,b mg/L (range) 6.11 6 6.75 (0.2-23.9) 5.32 6 7.98 (0.2-33.4) .75
D-dimer,b mg/L (range) 0.80 6 0.47 (0.23-1.71) 0.77 6 0.45 (0.32-1.92) .81
Current smoker, % 30 (6/20) 14 (3/21) .64
Hypertension, % 95 (19/20) 75 (15/20) .18
Statin use, % 40 (8/20) 45 (9/20) .99
Diabetes, % 55 (11/20) 41 (7/17) .61
Stroke, % 17 (3/18) 0 (0/19) .21
Angina, % 37 (7/19) 19 (4/21) .37
Cancer, % 26 (5/19) 29 (6/21) .99
Congestive heart failure, % 16 (3/19) 0 (0/21) .20
Myocardial infarction, % 42 (8/19) 25 (5/20) .43
Pulmonary disease, % 21 (4/19) 10 (2/21) .56
Atherosclerotic vascular disease,c % 74 (14/19) 33 (7/21) .03
Classic claudication symptoms, % 15 (3/20) 24 (5/21) .69
Antiplatelet use, % 50 (10/20) 71 (15/21) .27
Physical activity
Number of blocks walked last week 28.3 6 38.8 33.6 6 46.7 .70
Number of stair ﬂights climbed last week 6.2 6 8.1 17.7 6 19.1 .03
CRP, C-reactive protein.
aP values were obtained from two-sample t-tests or c2 tests.
bCRP and D-dimer data were only available for 16 survivors and 16 decedents from the WALCS and WALCS II cohorts. WALCS, Walking and Leg
Circulation Study.
cComprising stroke, angina, or myocardial infarction.
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between decedents and survivors with PAD were compared
using t-tests for continuous variables and c2 tests for cate-
gorical variables.
Self-Organizing Map. We used the Self-Organizing
Map (SOM) to create an ordered representation of multi-
dimensional metabolomic data to reveal complex correla-
tion structures among samples and metabolite patterns. An
algorithm similar to Makinen et al23 was used to perform
SOM analyses. Brieﬂy, we produced a map with 5 by 5
hexagonal units using a Gaussian neighborhood function
(2.4 samples per unit on average). The SOM algorithm
resulted in spectral models of neighboring units that are
more similar to each other than those from the remote sites
of the SOM. After the map was constructed, each of 61
spectra was allocated to its best-matching spectral model
(eg, a hexagonal unit) on the SOM. Samples mapped to the
same unit represent a cluster of closely related metabolomic
proﬁles. The interpretation of the SOM is provided in the
Appendix (online only). To observe the differences between
spectral models, the metabolic spectrum of each hexagonal
unit was represented according to the average intensity of
the key substructures of lipid or small molecules in the
spectra mapped to the certain unit within one unit radius.
RESULTS
Characteristics of PAD participants. The baseline
clinical characteristics of the participants are shown in theTable. There were no signiﬁcant differences in the
majority of the clinical variables between survivors and
decedents. However, the prevalence of several comorbid-
ities (eg, angina, stroke, myocardial infarction, and
pulmonary disease) was higher among the decedents, and
there is a signiﬁcant difference between the decedents and
survivors (74% vs 33%; P ¼ .03) in active atherosclerotic
vascular diseases (ie, a combination of stroke, angina, and
myocardial infarction). Additionally, the number of stair
ﬂights walked was signiﬁcantly higher in the survivor group
(6.2 vs 17.7; P ¼ .03). For the 20 decedents, seven died of
coronary heart disease or CVD, six died of cancer, ﬁve died
of non-coronary heart disease/CVD or noncancer causes,
and two died of an unknown cause.
Metabolic patterns of decedents vs survivors. We
observed a large number of spectrum signals with
distinct intensity levels between the decedent index,
decedent preindex, and survivor blood samples from
the diffusion-edited spectra. Speciﬁcally, 26% of signals
for index decedent samples vs survivor samples, 23% of
signals for preindex decedent samples vs survivor
samples, and 12% of signals for index decedent samples
vs preindex decedent samples were signiﬁcantly different
at P values <.05. In contrast, no distinct CPMG 1H
NMR metabolomic patterns were observed between
these three groups (data not shown). Thus, we focused
on the diffusion-edited spectra data for the remaining
analyses.
Fig 1. Self-Organizing Maps (SOMs) of 61 proton nuclear magnetic resonance (1H NMR) spectra of plasma from
peripheral arterial disease (PAD) patients with and without experiencing near-term death. Each hexagonal unit of the
SOM represents a speciﬁc metabolic model spectrum and the color coding represents the percentage estimate of
samples from a speciﬁc category (decedent index, decedent preindex, and survivor) mapped to the corresponding
model spectrum. A-C represent the SOMs of 21 survivor samples, 20 decedent preindex samples, and 20 decedent
samples, respectively.
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rate <10%) of the diffusion-edited spectral data from the
comparison between the decedent preindex samples and
the survivor samples. As shown in Fig 1, most survivor
samples shared metabolomic patterns on the upper-right
hexagonal units of the SOM while most decedent pre-
index and decedent index samples had similar metabolomic
patterns on the left and lower hexagonal units. For
example, most survivor samples (86%; Fig 2) had metabo-
lomic patterns characterizing metabolites from signals of
the following chemical groups: eCH3 (0.7 ppm), (e
CH2e)n (1.3 ppm), bCH2 (1.45 ppm), ]CHe
CH2CH2e (1.95 ppm), aCH2 (2.2 ppm), and CHe
CH2eCH] (2.82 ppm) of fatty acyl chain protons of
various lipid types as part of lipoproteins as well as
eN(CH3)3 (3.26 ppm) and NCH2 (3.6 ppm) from the
choline head group protons of phospholipids. The intensity
levels of these chemical signals are signiﬁcantly different
between survivors and decedents (Fig 3). Relative to
survivor samples, most of these chemical signals that have
higher (or lower) mean intensity levels in the decedent
preindex samples have even higher (or lower) mean inten-
sity levels in the decedent index samples, although none of
them reaches statistical signiﬁcance (P < .05).
Sensitivity and speciﬁcity of metabolic proﬁle for
predicting near-term mortality. 1H NMR metabolomic
proﬁles provide a high predictive accuracy for the near-
term all-cause deaths in these PAD participants. For the
classiﬁcation between decedent preindex samples and
survivor samples, the overall classiﬁcation performance wasoptimal at 78% (32 out of 41 participants), with a speci-
ﬁcity of 71% (15 out of 21 survivors) and a sensitivity of
85% (17 out of 20 decedents) using the top 40 to 150
chemical signals of the diffusion-edited data. The predictive
accuracy was similar when decedent index and survivor
samples were compared. Speciﬁcally, the overall classiﬁca-
tion success was optimal at 83% (34 out of 41 participants)
with a speciﬁcity of 86% (18 out of 21 survivors) and
a sensitivity of 80% (16 out of 20 decedents) using the top
10 to 20 chemical signals. The four decedents who were
misclassiﬁed included two who died of cancer, one who
died of CVD, and one who died of an unknown cause.
Logistic regression shows that the metabolomic signature
remained signiﬁcantly associated with near-term all-cause
death (P < 104) after adjustment for active atherosclerotic
diseases status.
DISCUSSION
Our results demonstrate that the global metabolomic
proﬁling of plasma differed between 20 PAD participants
who died within 8 months after their blood samples were
obtained and 21 PAD participants who survived for at least
30 months after their blood samples were obtained. Impor-
tantly, the metabolomics proﬁling of decedent preindex
samples shows that these differences are already detectable
more than 1 year before death. Since death involves a global
breakdown of the homeostatic regulation of multiple meta-
bolic pathways that fails to counter the overwhelming
destructive metabolic reactions,24 the dramatically altered
metabolic composition in decedents may reﬂect underlying
Fig 2. Three key metabolic model spectra of the Self-Organizing Map (SOM). A, The survivor model spectrum
mapped to the grid (1,5) in Fig 3, A. B, The decedent preindex model spectrum mapped to the grid (3,1) in Fig 3, B.
C, The decedent index model spectrum mapped to the grid (5,3) in Fig 3, C. The red curve indicates the current
metabolic model; the black curve indicates the mean spectrum over all 61 spectra, thus serving as a constant reference.
The proportional differences of each metabolic model spectrum and the mean spectrum are shown by the colored area
below each model spectrum.
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suggest that metabolomic proﬁling of plasma may be
a useful tool to delineate the pathophysiological and bio-
logic mechanisms immediately preceding death.
Our results show that the major chemical signals differ-
entiating survivors from decedents were derived from the
diffusion-edited proﬁling but were not from the CPMG
proﬁling, suggesting lipid metabolism may have a stronger
association with near-term death than other small mole-
cules such as carbohydrates or amino acids. Although
speciﬁc molecular mechanisms may exist in different
diseases, the lipid signature identiﬁed in the current study
may represent a common pathway associated with
mortality in different diseases. Evidence is emerging to
support this assertion. For example, large epidemiological
studies have found an increased risk of developing coro-
nary heart disease and a variety of cancers in individuals
with diabetes,25,26 suggesting the existence of common
molecular mechanisms that are associated with the devel-
opment of various chronic diseases. Additionally, our
metabolomics ﬁnding is in line with a recent transcriptomic
ﬁnding by Hirsch et al,27 who identiﬁed an unexpected
molecular link between lipid metabolism and diverse
human diseases including cancer, atherosclerosis, diabetes,
and autoimmune diseases. Structural analysis of our metab-
olomic data showed that the most signiﬁcant chemical
signals arose from lipoproteins and phospholipids. These
two lipid groups can be converted through arachidonic
acid metabolism to prostaglandins, which play a central
role in platelet aggregation, vascular smooth muscle tone,and inﬂammation.28 This suggests that these two lipid
groups have a fundamental role in plaque homeostasis
or pathophysiological changes prior to death.29 Experi-
mental studies also demonstrated that inhibition of cyclo-
oxygenase, the rate-limiting enzyme for conversion of
arachidonic acid to important signal molecules (ie, prosta-
glandins), has a profound effect on cellular functions in
many tissues, including tumor growth suppression and
reduction of atherosclerosis.30-33 Since the cyclooxygenase
pathway plays a critical role in inﬂammation, future investi-
gation is needed to determine whether these two groups of
lipid species (ie, those with fatty acyl chain protons of lipo-
proteins and the choline head group protons of phospho-
lipids) are involved in this pathway and induce further
inﬂammation or changes in other biological processes
related to the pathophysiology of all-cause near-term death.
These two groups of lipid species may also be associated
with physical activity. The survivor group of our study’s
participants had better walking performance than the dece-
dent group. A recent metabolomics analysis34 of the Fra-
mingham Heart Study participants showed that baseline
plasma concentration of metabolites in the lipolysis pathway
that were altered in response to exercise was associated with
cardiovascular ﬁtness. Furthermore, several cohort and twin
studies show that long-term leisure-time physical activity
affects serum concentrations of a wide spectrum of lipopro-
tein subclasses, independent of body mass index and age.35
Therefore, future studies will be needed to examine
whether our observation in the alteration of lipid proﬁling
is linked to physical activity e thereby identifying an
Fig 3. Concentration levels of substructures of lipid molecules from plasma samples of survivors and decedents.
Quantiﬁed were: A, eCH3 signal at 0.7 parts per million (ppm). B, (eCH2e)n signal at 1.3 ppm. C, bCH2 signal at
1.45 ppm. D, ]CHeCH2CH2e signal at 1.95 ppm. E, aCH2 signal at 2.2 ppm. F, ]CHeCH2eCH] signal at
2.82 ppm. G, e(NH3)3 signal at 3.26 ppm. H, NCH2 signal at 3.6 ppm. Statistically signiﬁcant levels for comparison
between survivor and preindex decedent and comparison between survivor and index decedent samples are indicated by
red star: *P < .05; **P < .01. Intensity levels are not signiﬁcantly different between preindex and index decedent
samples for all eight chemical signals.
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patients with PAD. The intensity levels of the majority of
these chemical signals show linear increases or decreases
from survivor to decedent preindex to decedent index
samples (Fig 3). Intensity levels are signiﬁcantly differentbetween survivors and decedent index samples and between
survivor and decedent preindex samples (except for bCH2),
but are not signiﬁcantly different between decedent
preindex and index samples. Since both decedent metabolo-
mics proﬁles are near-term mortality measurements (18.4 vs
JOURNAL OF VASCULAR SURGERY
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metabolites over the 1 year or so before death among the
decedents (but signiﬁcantly different from survivors)
suggests that these lipid signals are a robust metabolite
signature to discriminate those at risk for imminent acute
events including death. However, further prospective study
is needed, including conﬁrmation of these ﬁndings in
a larger cohort of individuals with PAD. Identifying these
speciﬁc metabolites using high-sensitive technologies such
as mass spectrometry may help elucidate metabolic mecha-
nisms of mortality and may lead to new therapies to
improve longevity.
Some limitations of the current study should be
acknowledged. First, the small sample size of our pilot study
does not allow adjustment for other risk factors and clinical
variables in our classiﬁcation model. Similarly, our study has
a low statistical power to evaluate the correlation between
metabolites and known risk factors such as cholesterol
levels, thereby limiting the clinical utility of the metabolo-
mic proﬁle in modifying the clinical course. Future studies
with a larger sample size are needed to conﬁrm the ﬁndings
reported here. Second, our pilot study did not have all the
clinical variables necessary to construct the 10-year Charl-
son comorbidity score.36 Therefore, we are not able to
assess the incremental predictive value of our metabolomics
proﬁling for near-termmortality in addition to the Charlson
comorbidity score. Third, 1H NMR proﬁling is advanta-
geous because it is capable of screening a large number of
metabolites and revealing a global metabolomic pattern.
However, the molecular species giving rise to the peaks
are generally unknown, and this method tends to have
a low sensitivity that can detect only highly abundant
metabolites.37 Further studies using technology with high
precision and accuracy such as liquid chromatography
mass spectrometry may identify unambiguously speciﬁc
lipid metabolites and other nonlipid metabolites that may
complement current existing biomarkers for near-term
mortality. Fourth, study participants were outpatients with
PAD. Our ﬁndings may not be generalizable to individuals
at risk for PAD or those with critical limb ischemia. Fifth, we
did not have data on diabetes mellitus severity. However, we
are unaware of evidence demonstrating that more severe
diabetes mellitus is associated with higher mortality in
PAD patients without critical limb ischemia.
In summary, our result, as a proof-of-principle, shows
that a speciﬁc metabolite signature from the lipid species
correlated well with near-term death. To our knowledge,
this is the ﬁrst study to examine the utility of metabolomics
proﬁling for near-term mortality prediction in any patient
population. Our results suggest that metabolomic proﬁling
may be a useful prognostic tool to identify individuals at
high risk for near-term mortality. However, conﬁrmation
of these ﬁndings in a larger cohort is needed. In addition,
further in-depth investigation of these metabolites is
required to understand how the alteration of these metab-
olites’ concentration inﬂuences the metabolic pathways
that are activated during the days and weeks leading up
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MEASUREMENT OF CLINICAL VARIABLES
Ankle-brachial index measurement. A hand-held
Doppler probe (Pocket-Dop II, Nicolet Vascular, Golden,
Colo) was used to measure systolic pressures in the right
brachial artery, right dorsalis pedis and posterior tibial
arteries, left dorsalis pedis and posterior tibial arteries, and
left brachial artery.
Total and high-density lipoprotein cholesterol
levels. Total cholesterol levelsweremeasuredbyusing enzy-
matic reaction with peroxidase-phenol-4-aminophenazone
indicator reaction. High-density lipoprotein cholesterol
levels were measured by using a direct enzymatic colori-
metric assay.
Cigarette smoking, body mass index, and medical
history. We determined smoking status by patient report
using a structured interview. Body mass index was calcu-
lated as weight in kilograms dividing by height in meters
squared. Diabetes status was determined based on patient
self-report in the SILC and the RRF clinical trials. In the
WALCS II, III cohorts, diabetes was considered present if
the participant was taking insulin or an oral hypoglycemic
agent or if a patient report of diabetes mellitus was
conﬁrmed by medical record review or a primary care
physician questionnaire. Hypertension was deﬁned as
either a patient report of physician-diagnosed hyperten-
sion or a physician report of a history of hypertension on
the primary care physician questionnaire. The patient
report of a physician diagnosis of each comorbid condi-
tion was used in the SILC and RRF clinical trials. In
WALCS cohorts, we obtained patient reports of physician-
diagnosed comorbidities, but the data were also adjudi-
cated from medical record review and a primary care
physician questionnaire.
D-dimer and CRP levels. D-dimer levels were
measured using an Asserachrom D-Di it (Diagnostica
Stago, Asniè res-sur-Seine, France) with an enzyme-
linked immunosorbent assay procedure. CRP levels were
measured using an immunotechnique on the Behring BN
II analyzer (Dade Behring, Wilmington, Del). CRP andD-dimer data were only available for 16 survivors and 16
decedents from the WALCS and WALCS II cohorts.
Physical activity. Patient-reported physical activity
was measured with a questionnaire derived from the Har-
vard Alumni Activity Survey.1 Participants were asked,
“During the last week, how many city blocks or their
equivalent did you walk? Let 12 city blocks equal 1 mile.”
and “In the last week, about how many ﬂights of stairs did
you climb up? A ﬂight is 10 steps.”
Statistical methods for chemical signal selection and
sample classiﬁcation. To assess the probability of false
positive ﬁndings, we used the positive False Discovery
Rate method proposed by Storey.2 For predicting all-
cause deaths, the leave-one-out cross validation proce-
dure with support vector machine classiﬁers was used to
evaluate the classiﬁcation accuracy. For each binned vari-
able, a c statistic to evaluate its discriminative power for
near-term death was calculated. Binned variables with the
largest c statistics were sequentially added to support vector
machine classiﬁers.
Interpretation of SOM. After the locations of the
metabolomic spectra on the SOM were obtained, color
coding was used for each hexagonal unit to represent the
percentage of a speciﬁc category of spectra within one
unit radius of a certain hexagonal unit. For example, if
two spectra of survivor samples are mapped to a certain
hexagonal unit, and eight spectra of survivor samples are
mapped to the nearby units, then there were 10 (2 þ 8)
spectra of survivor samples mapped to the certain unit
within one unit radius. If a total of 16 experimental spectra
were mapped to the certain unit within one unit radius, the
color value of the certain hexagon unit for survivor cate-
gory is 63% (10/16).
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